Ocuphire Shares Rally Premarket as FDA Approves Ryzumvi Eye Drops
27 September 2023 - 10:58PM
Dow Jones News
By Colin Kellaher
Shares of Ocuphire Pharma rose sharply in premarket trading
Wednesday after the ophthalmic biopharmaceutical company and
partner Viatris won U.S. Food and Drug Administration approval of
their Ryzumvi eye drops.
Ocuphire and Viatris on Wednesday said the approval covers
Ryzumvi for the treatment of pharmacologically-induced mydriasis
produced by adrenergic agonists or parasympatholytic agents.
Ocuphire, based in Farmington Hills, Mich., last year inked a
licensing agreement for the development and commercialization of
Ryzumvi with FamyGen Life Sciences, which healthcare company
Viatris acquired earlier this year.
Ocuphire and Viatris said they expect Ryzumvi to be commercially
available in the U.S. in the first half of 2024.
Shares of Ocuphire, which closed Tuesday at $4.02, were recently
up 9.5% to $4.40 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 27, 2023 08:43 ET (12:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Viatris (NASDAQ:VTRS)
Historical Stock Chart
From May 2024 to Jun 2024
Viatris (NASDAQ:VTRS)
Historical Stock Chart
From Jun 2023 to Jun 2024